Company Description
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases.
It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT antibody, which has demonstrated clinical results as a conditioning agent for stem cell transplant and mast cell mediated diseases, such as chronic urticarias and allergic asthma; and KP-701, a novel, dual-acting anti-CD79BxCD32B monoclonal antibody (mAb) for autoantibody-mediated disorders.
The company is based in Redwood City, California.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Jeetinder Mahal |
Contact Details
Address: 2200 Bridge Pkwy, Suite #102 Redwood City, California 94065 United States | |
| Phone | 650-549-1400 |
| Website | jaspertx.com |
Stock Details
| Ticker Symbol | JSPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1788028 |
| CUSIP Number | 471871202 |
| ISIN Number | US4718712023 |
| Employer ID | 84-2984849 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jeetinder Singh Mahal M.B.A. | President, Chief Executive Officer and Director |
| Thomas G. Wiggans | Executive Chairman |
| Dr. Judith Anne Shizuru M.D., Ph.D. | Co-Founder, Member of Scientific Advisory Board and Director |
| Herbert C. Cross CPA | Chief Financial Officer and Corporate Secretary |
| Matthew E. Ros | Chief Operating Officer |
| Alex Gray | Head of Investor Relations |
| Matthew Ford | Senior Vice President of Human Resources |
| Dr. Gregory F. Keenan M.D. | Chief Medical Officer |
| Dr. Wenru Song M.D., Ph.D. | Executive Vice President and Head of Research & Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 15, 2026 | 8-K | Current Report |
| Oct 14, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Oct 9, 2026 | PRE 14A | Other preliminary proxy statements |
| Oct 7, 2026 | 8-K | Current Report |
| Oct 7, 2026 | SC TO-I | Filing |
| Oct 5, 2026 | 8-K | Current Report |
| Oct 5, 2026 | 8-K/A | [Amend] Current report |
| Oct 1, 2026 | 8-K/A | [Amend] Current report |
| Sep 28, 2026 | 8-K | Current Report |
| Sep 24, 2026 | 25-NSE | Filing |